Literature DB >> 9576487

Sulfation in high endothelial venules: cloning and expression of the human PAPS synthetase.

J P Girard1, E S Baekkevold, F Amalric.   

Abstract

High endothelial venules (HEVs) are specialized postcapillary venules found in lymphoid organs and chronically inflamed tissues that support high levels of lymphocyte extravasation from the blood. Studies with chlorate, a metabolic inhibitor of sulfation, had previously revealed that production of PAPS (3'-phosphoadenosine-5'-phosphosulfate), the high-energy donor of sulfate, is required for sulfation and high-affinity recognition of HEV sialomucins GlyCAM-1 and CD34 by the lymphocyte homing receptor L-selectin. Here, we report the molecular characterization of a novel 2.5 kb human cDNA from MECA-79+ HEV-derived endothelial cells that encodes the target of chlorate, PAPS synthetase, a multifunctional enzyme containing domains for both ATP sulfurylase and adenosine-5'-phosphosulfate kinase. Functional expression of the isolated cDNA in Chinese hamster ovary cells results in high levels of PAPS synthesis, which is abolished by treatment of the transfected cells with chlorate. Northern blot analysis reveals a wide tissue distribution of PAPS synthetase mRNA in the human body, suggesting that human PAPS synthetase may be important for sulfation not only of HEV sialomucins, but also of many other molecules, including mucins such as the P-selectin ligand PSGL-1, proteoglycans, hormones, neurotransmitters, drugs, and xenobiotics.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9576487     DOI: 10.1096/fasebj.12.7.603

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  9 in total

1.  Endothelial ligands for L-selectin: from lymphocyte recirculation to allograft rejection.

Authors:  S D Rosen
Journal:  Am J Pathol       Date:  1999-10       Impact factor: 4.307

2.  Heterogeneity of endothelial cells: the specialized phenotype of human high endothelial venules characterized by suppression subtractive hybridization.

Authors:  J P Girard; E S Baekkevold; T Yamanaka; G Haraldsen; P Brandtzaeg; F Amalric
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

3.  Human natural killer-1 sulfotransferase (HNK-1ST)-induced sulfate transfer regulates laminin-binding glycans on α-dystroglycan.

Authors:  Naoki Nakagawa; Hiroshi Manya; Tatsushi Toda; Tamao Endo; Shogo Oka
Journal:  J Biol Chem       Date:  2012-07-16       Impact factor: 5.157

4.  Molecular cloning and functional analysis of SUT-1, a sulfate transporter from human high endothelial venules.

Authors:  J P Girard; E S Baekkevold; J Feliu; P Brandtzaeg; F Amalric
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

5.  Characterization and expression of human bifunctional 3'-phosphoadenosine 5'-phosphosulphate synthase isoforms.

Authors:  Hirotoshi Fuda; Chikara Shimizu; Young C Lee; Harukuni Akita; Charles A Strott
Journal:  Biochem J       Date:  2002-07-15       Impact factor: 3.857

6.  Human PAPS synthase isoforms are dynamically regulated enzymes with access to nucleus and cytoplasm.

Authors:  Elisabeth Schröder; Lena Gebel; Andrey A Eremeev; Jessica Morgner; Daniel Grum; Shirley K Knauer; Peter Bayer; Jonathan W Mueller
Journal:  PLoS One       Date:  2012-01-05       Impact factor: 3.240

Review 7.  N-Acetylcysteine and Other Sulfur-Donors as a Preventative and Adjunct Therapy for COVID-19.

Authors:  Heidi N du Preez; Colleen Aldous; Hendrik G Kruger; Lin Johnson
Journal:  Adv Pharmacol Pharm Sci       Date:  2022-08-10

8.  A GlycoGene CRISPR-Cas9 lentiviral library to study lectin binding and human glycan biosynthesis pathways.

Authors:  Yuqi Zhu; Theodore Groth; Anju Kelkar; Yusen Zhou; Sriram Neelamegham
Journal:  Glycobiology       Date:  2021-04-01       Impact factor: 4.313

9.  The host cell sulfonation pathway contributes to retroviral infection at a step coincident with provirus establishment.

Authors:  James W Bruce; Paul Ahlquist; John A T Young
Journal:  PLoS Pathog       Date:  2008-11-14       Impact factor: 6.823

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.